The lethality for BALB/c mice of 1,3-bis(2-chloroethyl)-1-nitrosourea, cytosine arabinoside, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, hydroxyurea, mithramycin, a polymyxin-like antibiotic (SQ 21,286) 
ministered mithramycin and LPS or TIC-mustard administered 24 h after LPS synergistically killed mice. Concanavalin A potentiated the lethality of TIC-mustard but not of eight other drugs tested. Pretreatment of mice with LPS or lipid A complexed to concanavalin A rendered mice resistant to the lethal action of LPS alone or combinations of LPS and mithramycin. Mithramycintreated mice were killed by minute amounts of LPS. Mice sensitized to LPS by mithramycin were used to detect endotoxic activity in biological materials, such as commercially available enzymes, and in a complex of lipid A with concanavalin A.
Sublethal doses of many antitumor drugs given in combination with a sublethal dose of bacterial lipopolysaccharide (LPS) result in marked lethality for the treated mice (16) . Until recently, only antitumor drugs that inhibit protein or ribonucleic acid synthesis were known to potentiate the lethality of LPS. It is now recognized, however, that agents that affect deoxyribonucleic acid (DNA) synthesis, structure, and function (for example, 5-fluorouracil, 5-fluorouracil deoxyriboside, or chlorambucil [2 ] ) can interact with LPS in vivo, leading to increased lethality for mice. Because such potentiated toxicities involving antitumor drugs and LPS may have clinical signiticance, their prevalence needs to be determined. Accordingly, the capability of 10 drugs to interact in vivo with LPS to enhance mouse lethality has been assessed. Most of the selected drugs have been used clinically and most affect DNA synthesis, structure or function.
Concanavalin A can substitute for LPS enhancing the lethal action of 5-fluorouracil (N. M. Marecki, S. G. Bradley, A. E. Munson, and D. C. Drummond, Toxicol. Appl. Pharmacol., in press). It has been suggested therefore that a mitogen such as concanavalin A might be able to substitute for LPS in enhancing the lethality of other antitumor drugs, particularly those affecting DNA (3) . Accordingly, the capability of drugs to interact in vivo with concanavalin A has been assessed.
Of 10 antibiotics and antitumor drugs examined in this study, only mithramycin or 5-[3,3-bis(2-chloroethyl)-1-triazeno]-imidazole-4-carboxamide (TIC-mustard), in combination with LPS, resulted in enhanced lethality for mice. Mice sensitized to LPS by mithramycin were used to detect endotoxic activity in biological materials.
MATERIALS AND METHODS
Male BALB/c mice weighing 22 to 27 g were used in all-experiments. Mice were obtained from Flow Research Animals, Inc., Dublin, Va. They were allowed to adjust to their new environment for at least 1 week prior to experimentation. The mice were given free access to food (Purina Lab Chow, Purina Ralston Corp., St. Louis, Mo.) and water. All drug solutions were prepared so that 0.01 ml/g of mouse weight would provide the desired dose. All drugs and LPS injections were given simultaneously by the intraperitoneal route unless otherwise specified. The 
RESULTS
The lethality of 10 drugs, administered simultaneously with E. coli LPS was measured (Table 1) . Only mithramycin in combination with LPS markedly enhanced lethality when administered simultaneously, cytosine arabinoside or procarbazine in combination with LPS somewhat enhanced lethality.
TIC-mustard, administered 24 h after LPS, markedly enhanced mouse lethality ( Table 2) . Administration of BCNU, CCNU, hydroxyurea or the polymyxin-like antibiotic SQ 21, 286 (13) 24 h before or after LPS, at the doses reported in Table 1 , did not lead to enhanced mouse lethality. The moderate enhanced lethality noted with a simultaneous combination of procarbazine and LPS was also observed when LPS was administered 24 h before procarbazine (6 mice dead of 20 given both agents versus 0 mice dead of 10 treated with either agent alone).
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The combination of mithramycin and LPS was selected for further study. Death due to mithramycin alone, LPS alone, or the combination usually occurred within 24 h after challenge. The mean lethal dose on day 4 for mithramycin alone was 1.7 mg/kg (95% confidence limits, 1.6 to 1.9), and for E. coli 026:B6 Boivin LPS was 11.2 mg/kg (95% confidence limits, 9.9 to 13.4). Administration of mithramycin with 2 mg of LPS per kg resulted in a 19-fold reduction in the mean lethal dose of the drug on day 4 (Fig. 1) . Administration of LPS with 0.25 mg of mithramycin per kg resulted in a 100-fold reduction in the mean lethal dose of LPS on day 5 (Fig. 2) . The mean lethal dose of mice administered 0.5 mg of mithramycin per kg was less than 10 ,g of LPS per kg and that for mice administered 1 mg of mithramycin per kg was less than 1 ,ug of LPS per kg. The dose-effect curves for the combinations were parallel to those for mithramycin alone and LPS alone, indicating that the lethal action of the combination did not involve a new toxic mechanism. An isobologram based up,on the 50% lethal doses of combinations of mithramycin and LPS established that this in vivo interaction was markedly synergistic (Fig. 3) . Enhanced lethality of combinations of mithramycin and LPS occurred when the two agents were administered simultaneously but not when 24 h separated the two challenges ( Table 4 ). The enhanced lethality of combinations of mithramycin and LPS was not affected by the route of administration of mithramycin. LPS given ip or intravenous (iv) rendered the mice hyperreactive to mithramycin administered ip or iv ( (Table 6 ).
Mice were administered E. coli 026:B6 (B) LPS daily for 4 days to render them resistant to a challenge of LPS that kills normal mice. Mice pretreated with LPS were significantly protected from the lethal action of mithramycin in combination with LPS (Table 7) . Sinmilarly, mice administered lipid A complexed to concanavalin A daily for 4 days were rendered 1 .0 1O5 (Table 8) .
The mithramycin-treated mouse was used as an indicator of endotoxic activity in several commercial enzyme preparations and other biological materials. Of the four enzymes tested, only pronase contained endotoxic activity as assayed by both the mouse-lethality assay (Table 9 ) and by gelation of the Limulus amoebocyte lysate (E-TOXATE, Sigma). Of the five concanavalin A complexes tested, only two possessed endotoxic activity as assayed both by the mouse lethality assay and by gelation of Limulus amoebocyte lysate. The two complexes possessed several magnitudes less activity than LPS and the myristic acid-concanavalin A complex was less than one-tenth as active as the lipid A-concanavalin A complex (Table 9 ).
DISCUSSION
Of the 10 drugs and antibiotics examined in this study, six affect DNA synthesis, structure, or function (BCNU, CCNU, cytosine arabinoside, hydroxyurea, procarbazine, and TIC-mustard) (4, 15, 20) . Mithramycin is a potent inhibitor of ribonucleic acid synthesis (21) . Only mithramycin of these 10 agents interacts in vivo with LPS to enhance lethality markedly when administered in simultaneous combinations. TIC-mustard enhances lethality for mice when LPS is given before the antitumor drug. Accordingly, existence of synergistic toxicities involving an antitumor drug and LPS cannot be ruled out unless sequence of administration of the two agents is examined.
The diversity of the adverse effects of combinations of selected antitumor drugs and LPS may be a factor in the failure of physicians to clinically recognize synergistic toxicity as a problem. Moreover, when physicians are dealing with a seriously ill patient, there is a tendency to explain puzzling symptoms or episodes as the manifestation of the patient's grave state of health. Because a wide assortment of gram-negative bacteria can serve as the LPS source (11) and because bacteremia and fevers of unknown etiology occur frequently in patients with neoplastic disease (9) , the clinical investigator should be aware of the possible additional hazard associated with chemotherapy in patients with concurrent bacterial infections. Moreover, it is conceivable that a protocol examining drug toxicity in animals treated with LPS may be more predictive of adverse effects in patients than a protocol examining drug toxicity in a variety of normal animals.
Death of mice given TIC-mustard and LPS or concanavalin A at doses that are sublethal individually is probably due to the toxic action of TIC-mustard. LPS or concanavalin A may cause lymphoid cells to become more uniformly susceptible to the lethal action of the alkylating agent (6) .
Death of mice given mithramycin and LPS at doses that are sublethal individually is probably due to the toxic action of LPS. In general, inhibitors of protein or ribonucleic acid synthesis render mice hyperreactive to LPS (18) . Bates and Margolin (1) have established that LPS induces potentially lethal renal failure in the mouse.
It has been demonstrated that lipid A is the component of LPS responsible for mitogenicity (13) and pyrogenicity (8) . In addition, we suggest that lipid A is responsible for the synergistic interaction of LPS and antitumor drugs.
The mnithramycin-treated mouse is a sensitive indicator for endotoxic activity in complex materials. The specificity of the lethal effect can be assessed by rendering the mice resistant to LPS by pretreatment. The mithramycin-treated mouse is comparable to the actinomycin Dtreated mouse (5, 13) for detecting minute amounts of endotoxin. We were able to detect endotoxic activity in a complex of concanavalin A and myristic acid by using the mithramycintreated mouse as the indicator. It is not known whether this endotoxic activity is due to contamination of the myristic acid or to reconstitution of a legitimate active site of the endotoxin molecule. Rosenstreich et al. (17) have demonstrated that N-palmitoyl D-glucosamine possesses at least one attribute of endotoxin, mitogenicity for B-cells. A study of the biological properties of fatty acids complexed to a protein carrier may make it possible to develop structure-function relationships for bacterial LPS.
